A potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist, MK-8825, inhibits responses to nociceptive trigeminal activation: Role of CGRP in orofacial pain

Experimental Neurology

Volumn 271, Issue , 2015, Pages 95-103

  Romero Reyes, Marcela ^a   Pardi, Vanessa ^a,c   Akerman, Simon ^a,b  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anti CGRP; CGRP; Muscle; Nociception; Orofacial; Pain; TMDs; Trigeminal

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; INTERLEUKIN 6; MK 8825; UNCLASSIFIED DRUG; CYTOKINE; FREUND ADJUVANT; MK-8825; PROTEIN V FOS; PYRIDINE DERIVATIVE; SPIRO COMPOUND;

ACUTE OROFACIAL MASSETERIC MUSCLE PAIN; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; FEMALE; GROOMING; IMMUNOREACTIVITY; MOUSE; MYALGIA; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRIGEMINAL NUCLEUS; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FACIAL PAIN; HEMISPHERIC DOMINANCE; IN VITRO STUDY; MASSETER MUSCLE; METABOLISM; PAIN MEASUREMENT; PATHOPHYSIOLOGY; TIME; TRIGEMINUS GANGLION;

ANALYSIS OF VARIANCE; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FACIAL PAIN; FEMALE; FREUND'S ADJUVANT; FUNCTIONAL LATERALITY; IN VITRO TECHNIQUES; MASSETER MUSCLE; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS V-FOS; PAIN MEASUREMENT; PYRIDINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SPIRO COMPOUNDS; TIME FACTORS; TRIGEMINAL GANGLION;

EID: 84930204117     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.05.005     Document Type: Article

References (54)

1. Akerman S., Romero-Reyes M. Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine. Expert. Rev. Neurother. 2013, 13:1041-1059.
2. Asghar M.S., et al. Evidence for a vascular factor in migraine. Ann. Neurol. 2011, 69:635-645.
3. Assas B.M., et al. Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. Front. Neurosci. 2014, 8:23.
4. Bell I.M., et al. MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats. Bioorg. Med. Chem. Lett. 2012, 22:3941-3945.
5. Benemei S., et al. CGRP receptors in the control of pain and inflammation. Curr. Opin. Pharmacol. 2009, 9:9-14.
6. Biella G., et al. Facilitatory role of calcitonin gene-related peptide (CGRP) on excitation induced by substance P (SP) and noxious stimuli in rat spinal dorsal horn neurons. An iontophoretic study in vivo. Brain Res. 1991, 559:352-356.
7. Brain S.D., et al. The contribution of calcitonin gene-related peptide (CGRP) to neurogenic vasodilator responses. Agents Actions 1993, 38:C19-C21. (Spec No).
8. Cady R.J., et al. Calcitonin gene-related peptide promotes cellular changes in trigeminal neurons and glia implicated in peripheral and central sensitization. Mol. Pain 2011, 7:94.
9. De Felice M., et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann. Neurol. 2010, 67:325-337.
10. Dessem D., Lovering R.M. Repeated muscle injury as a presumptive trigger for chronic masticatory muscle pain. Pain Res. Treat. 2011, 2011:647967.
11. Diener H.C., et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011, 31:573-584.
12. Dina O.A., et al. Role of interleukin-6 in chronic muscle hyperalgesic priming. Neuroscience 2008, 152:521-525.
13. Dodick D.W., et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014, 13:1100-1107.
14. Dodick D.W., et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014, 13:885-892.
15. Dworkin S.F. Temporomandibular disorder (TMD) pain-related disability found related to depression, nonspecific physical symptoms, and pain duration at 3 international sites. J. Evid. Based Dent. Pract. 2011, 11:143-144.
16. Dworkin S., et al. Epidemiology of signs and symptoms in temporomandibular disorders: clinical signs in cases and controls. J. Am. Dent. Assoc. 1990, 120:273-281.
17. Field A. Discovering Statistics Using SPSS 2009, Sage Publishing Ltd., London.
18. Franco A.L., et al. Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J. Orofac. Pain 2011, 24:287-292.
19. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 1993, 33:48-56.
20. Goadsby P.J., et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 1990, 28:183-187.
21. Goncalves D.A., et al. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache 2010, 50:231-241.
22. Goncalves D.A., et al. Temporomandibular disorders are differentially associated with headache diagnoses: a controlled study. Clin. J. Pain 2011, 27:611-615.
23. Gonçalves D.A., et al. How to investigate and treat: migraine in patients with temporomandibular disorders. Curr. Pain Headache Rep. 2012, 16:359-364.
24. Hammond D.L., et al. Morphine or U-50,488 suppresses Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat. J. Comp. Neurol. 1992, 315:244-253.
25. Ho T.W., et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008, 70:1304-1312.
26. Ikeda T., et al. Differential rostral projections of caudal brainstem neurons receiving trigeminal input after masseter inflammation. J. Comp. Neurol. 2003, 465:220-233.
27. Imbe H., et al. Masseteric inflammation-induced Fos protein expression in the trigeminal interpolaris/caudalis transition zone: contribution of somatosensory-vagal-adrenal integration. Brain Res. 1999, 845:165-175.
28. Imbe H., et al. Orofacial deep and cutaneous tissue inflammation and trigeminal neuronal activation. Implications for persistent temporomandibular pain. Cells Tissues Organs 2001, 169:238-247.
29. Kehl L.J., et al. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 2000, 85:333-343.
30. Lam D.K., et al. Neural mechanisms of temporomandibular joint and masticatory muscle pain: a possible role for peripheral glutamate receptor mechanisms. Pain Res. Manag. 2005, 10:145-152.
31. Lassen L.H., et al. CGRP may play a causative role in migraine. Cephalalgia 2002, 22:54-61.
32. Lian B., et al. Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity. Brain Res. 2010, 1358:64-70.
33. Machado L.P., et al. The prevalence of clinical diagnostic groups in patients with temporomandibular disorders. Cranio 2009, 27:194-199.
34. Manjavachi M., et al. Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Pain 2010, 151:345-355.
35. Markowitz S., et al. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J. Neurosci. 1987, 7:4129-4136.
36. Mitrirattanakul S., Merrill R.L. Headache impact in patients with orofacial pain. J. Am. Dent. Assoc. 2006, 137:1267-1274.
37. Ohlen A., et al. Substance P and calcitonin gene-related peptide: immunohistochemical localisation and microvascular effects in rabbit skeletal muscle. Naunyn Schmiedebergs Arch. Pharmacol. 1987, 336:87-93.
38. Okeson J.P. Bell's Oral and Facial Pain 2014, Quintessence Publishing Co, Inc., Illinois USA.
39. Oku R., et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987, 403:350-354.
40. Olesen J., et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 2004, 350:1104-1110.
41. Ottoni E.B. EthoLog 2.2: a tool for the transcription and timing of behavior observation sessions. Behav. Res. Methods Instrum. Comput. 2000, 32:446-449.
42. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2003, Academic Press, London.
43. Peroutka S.J. Neurogenic inflammation and migraine: implications for the therapeutics. Mol. Interv. 2005, 5:304-311.
44. Poulos A.M., et al. Compensation in the neural circuitry of fear conditioning awakens learning circuits in the bed nuclei of the stria terminalis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14881-14886.
45. Ro J.Y., et al. Innocuous jaw movements increase c-fos expression in trigeminal sensory nuclei produced by masseter muscle inflammation. Pain 2003, 104:539-548.
46. Romero-Reyes M., Uyanik J.M. Orofacial pain management: current perspectives. J. Pain Res. 2014, 7:99-115.
47. Romero-Reyes M., et al. Spontaneous behavioral responses in the orofacial region: a model of trigeminal pain in mouse. Headache 2013, 53:137-151.
48. Salvatore C.A., et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J. Pharmacol. Exp. Ther. 2010, 333:152-160.
49. Smullin D.H., et al. Interactions between substance P, calcitonin gene-related peptide, taurine and excitatory amino acids in the spinal cord. Pain 1990, 42:93-101.
50. Sugiyo S., et al. Trigeminal transition zone/rostral ventromedial medulla connections and facilitation of orofacial hyperalgesia after masseter inflammation in rats. J. Comp. Neurol. 2005, 493:510-523.
51. Sun R.Q., et al. The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin. Pain 2003, 104:201-208.
52. Sun R.Q., et al. Calcitonin gene-related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and central sensitization. J. Neurophysiol. 2004, 92:2859-2866.
53. Zhou Q., et al. Persistent Fos protein expression after orofacial deep or cutaneous tissue inflammation in rats: implications for persistent orofacial pain. J. Comp. Neurol. 1999, 412:276-291.
54. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.